ConductScience.org, home

Paper3535593

Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages.

Crowle AJ and 2 others. Am Rev Respir Dis, 1986. Cited by 51 papers, by iCite.

Cite this record

ConductScience Library. Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Papers, record 3535593. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3535593

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages.
PubMed
Journal
Am Rev Respir Dis
PubMed
Year
1986
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
51
iCite
Relative citation ratio, by iCite
1.85
iCite
Revised in PubMed
2013-11-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Crowle AJA J
2Sbarbaro JAJ A
3May MHM H

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MacrophagesMajor topic
MycobacteriumMajor topic
Nontuberculous MycobacteriaMajor topic
PyrazinamideMajor topic
Adult
Bacteriological Techniques
Cells, Cultured
Dose-Response Relationship, Drug
Humans
Middle Aged
Osmolar Concentration
Time Factors

Source PubMed

Download CSV of topics

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.

PMIDTitleJournalYearIn PapersSource
39240337Therapeutic drug monitoring in tuberculosis.Eur J Clin Pharmacol2024https://conductscience.org/library/papers/39240337PubMed
38071218Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide.Nat Commun2023https://conductscience.org/library/papers/38071218PubMed
31669220Impact of the host environment on the antitubercular action of pyrazinamide.EBioMedicine2019https://conductscience.org/library/papers/31669220PubMed
26967493The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB.PLoS Comput Biol2016https://conductscience.org/library/papers/26967493PubMed
25348525High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/25348525PubMed
22470120Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.Antimicrob Agents Chemother2012https://conductscience.org/library/papers/22470120PubMed
20156156
Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.
Curr Clin Pharmacol2010https://conductscience.org/library/papers/20156156PubMed
15673774Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/15673774PubMed
12121929Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/12121929PubMed
11914348Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.J Bacteriol2002https://conductscience.org/library/papers/11914348PubMed
10796561Fully intermittent dosing with drugs for tuberculosis.Cochrane Database Syst Rev2000https://conductscience.org/library/papers/10796561PubMed
10496301Pharmacokinetic factors in the modern drug treatment of tuberculosis.Clin Pharmacokinet1999https://conductscience.org/library/papers/10496301PubMed
10348747Intrapulmonary concentrations of pyrazinamide.Antimicrob Agents Chemother1999https://conductscience.org/library/papers/10348747PubMed
9784514Differential growth characteristics and streptomycin susceptibility of virulent and avirulent Mycobacterium tuberculosis strains in a novel fibroblast-mycobacterium microcolony assay.Infect Immun1998https://conductscience.org/library/papers/9784514PubMed
9303411Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9303411PubMed
3129990Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis.Antimicrob Agents Chemother1988https://conductscience.org/library/papers/3129990PubMed
3126704Radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis in egg-yolk-enriched BACTEC 12A medium.Antimicrob Agents Chemother1988https://conductscience.org/library/papers/3126704PubMed
2802553Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2802553PubMed
2492972Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages.Infect Immun1989https://conductscience.org/library/papers/2492972PubMed
2127346Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2127346PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3535593

GET https://conductscience.org/api/papers/v1/3535593/cited_by?page=2